Regional differences in naloxone modulation of Δ9-THC induced Fos expression in rat brain

Neuropharmacology

Volumn 44, Issue 2, 2003, Pages 264-274

  Allen, K V ^a   McGregor, I S ^b   Hunt, G E ^b   Singh, M E ^a   Mallet, P E ^a  

^a UNIVERSITY OF NEW ENGLAND   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Analgesia; Appetite; C fos; Cannabinoid; Fos; Hypothalamus; Naloxone; Opioid; Reward; THC

Indexed keywords

DRONABINOL; DRUG ADDITIVE; NALOXONE; PROTEIN FOS; RIMONABANT;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; APPETITE; ARTICLE; CAUDATE NUCLEUS; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DRUG RECEPTOR BINDING; HYPOTHALAMUS NUCLEUS; HYPOTHALAMUS VENTROMEDIAL NUCLEUS; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INSULA; LOCOMOTION; MALE; NEUROANATOMY; NEUROLEPTANALGESIA; NONHUMAN; PERIAQUEDUCTAL GRAY MATTER; PRIORITY JOURNAL; PROTEIN INTERACTION; PUTAMEN; RAT; STRIA TERMINALIS; THALAMUS MIDLINE NUCLEUS; VENTRAL TEGMENTUM;

EID: 0037293041     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(02)00364-7     Document Type: Article

References (66)

1. Ameri A. The effects of cannabinoids on the brain. Progress in Neurobiology. 58:1999;315-348.
2. Amir S., Cain S., Sullivan J., Robinson B., Stewart J. In rats, odor-induced Fos in the olfactory pathways depends on the phase of the circadian clock. Neuroscience Letters. 272:1999;175-178.
3. Arnold J.C., Topple A.N., Mallet P.E., Hunt G.E., McGregor I.S. The distribution of cannabinoid-induced Fos expression in rat brain: Differences between the Lewis and Wistar strain. Brain Research. 921:2001;240-255.
4. Beltramino C. Ventral premammillary nuclei mediate pheromonal-induced LH release stimuli in the rat. Neuroendocrinology. 41:1985;119-124.
5. Bidaut-Russell M., Howlett A.C. Cannabinoid receptor-regulated cycle AMP accumulation in the rat striatum. Journal of Neurochemistry. 57:1991;1769-1773.
6. Braida D., Pozzi M., Cavallini R., Sala M. Conditioned place preference induced by the cannabinoid agonist CP 55,940: Interaction with the opioid system. Neuroscience. 104:2001;923-926.
7. Braida D., Pozzi M., Parolaro D., Sala M. Intracerebral self-administration of the cannabinoid receptor agonist CP 55,940 in the rat: interaction with the opioid system. European Journal of Pharmacology. 413:2001;227-234.
8. Burkey A.R., Carstens E., Wenniger J.J., Tang J., Jasmin L. An opioidergic cortical antinociception triggering site in the agranular insular cortex of the rat that contributes to morphine antinociception. Journal of Neuroscience. 16:1996;6612-6623.
9. Cadoni C., Pisanu A., Solinas M., Acquas E., Di Chiara G. Behavioural sensitization after repeated exposure to Delta(9)-tetrahydrocannabinol and cross-sensitization with morphine. Outcomes Management. 158:2001;259-266.
10. Carr K.D. Differential effects of mu and kappa opioid antagonists on Fos-like immunoreactivity in extended amygdala. Brain Research. 822:1999;34-42.
11. Chen J., Paredes W., Li J., Smith D., Lowinson J., Gardner E.L. Δ9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis. Psychopharmacology. 102:1990;156-162.
12. Corchero J., Fuentes J.A., Manzanares J. Δ9-Tetrahydrocannabinol increases proopiomelanocortin gene expression in the arcuate nucleus of the rat hypothalamus. European Journal of Pharmacology. 323:1997;193-195.
13. Datiche F., Roullet F., Cattarelli M. Expression of Fos in the piriform cortex after acquisition of olfactory learning: An immunohistochemical study in the rat. Brain Research Bulletin. 55:2001;95-99.
14. Davis M. Are different parts of the extended amygdala involved in fear versus anxiety? Biological Psychiatry. 44:1998;1239-1247.
15. De Fonseca F.R., Carrera M.R.A., Navarro M., Koob G.F., Weiss F. Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science. 276:1997;2050-2054.
16. De Vries T.J., Shaham Y., Homberg J.R., Crombag H., Schuurman K., Dieben J., Vanderschuren L., Schoffelmeer A.N.M. A cannabinoid mechanism in relapse to cocaine seeking. Nature Medicine. 7:2001;1151-1154.
17. DeRossett S.E. Effects of naloxone and diprenorphine on spontaneous activity in rats and mice. Pharmacology, Biochemistry & Behavior. 17:1982;347-351.
18. Di Marzo V., Goparaju S.K., Wang L., Liu J., Batkai S., Jarai Z., Fezza F., Miura G.I., Palmiter R.D., Sugiura T., Kunos G. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature. 410:2001;822-825.
19. Erb S., Stewart J. A role for the bed nucleus of the stria terminalis, but not the amygdala, in the effects of corticotropin-releasing factor on stress-induced reinstatement of cocaine seeking. Journal of Neuroscience. 19:1999;C1-C6.
20. Erdtmann-Vourliotis M., Mayer P., Riechert U., Hollt V. Acute injection of drugs with low addictive potential (Δ9-tetrahydrocannabinol, 3,4-methylenedioxymethamphetamine, lysergic acid diamide) causes a much higher c-fos expression in limbic brain areas than highly addicting drugs (cocaine and morphine). Molecular Brain Research. 71:1999;313-324.
21. Fant R.V., Heishman S.J., Bunker E.B., Pickworth W.B. Acute and residual effects of marijuana in humans. Pharmacology, Biochemistry and Behavior. 60:1998;777-784.
22. Gallate J.E., Saharov T., Mallet P.E., McGregor I.S. Increased motivation for beer in rats following administration of a cannabinoid CB1 receptor agonist. European Journal of Pharmacology. 370:1999;233-240.
23. Garcia M.M., Brown H.E., Harlan R.E. Alterations in immediate-early gene proteins in the rat forebrain induced by acute morphine injection. Brain Research. 692:1995;23-40.
24. Gardner E.L., Lowinson J. Marijuana's interaction with brain reward systems: update 1991. Pharmacology, Biochemistry & Behavior. 40:1991;571-580.
25. Gestreau C., Le Guen S., Besson J.M. Is there tonic activity in the endogenous opioid systems? A c-Fos study in the rat central nervous system after intravenous injection of naloxone or naloxone-methiodide. Journal of Comparative Neurology. 427:2000;285-301.
26. Heinrichs S.C., Menzaghi F., Schulteis G., Koob G.F., Stinus L. Suppression of corticotropin-releasing factor in the amygdala attenuates aversive consequences of morphine withdrawal. Behavioural Pharmacology. 6:1995;74-80.
27. Herkenham M., Lynn A.B., de Costa B.R., Richfield E.K. Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Research. 547:1991;267-274.
28. Jamshidi N., Taylor D.A. Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. British Journal of Pharmacology. 134:2001;1151-1154.
29. Kang W., Wilson S.P., Wilson M.A. Overexpression of proenkephalin in the amygdala potentiates the anxiolytic effects of benzodiazepines. Neuropsychopharmacology. 22:2000;77-88.
30. Kirkham T.C., Williams C.M. Synergistic effects of opioid and cannabinoid antagonists on food intake. Psychopharmacology. 153:2001;267-270.
31. Ladabaum U., Minoshima S., Owyang C. Pathobiology of visceral pain: molecular mechanisms and therapeutic implications V. Central nervous system processing of somatic and visceral sensory signals. American Journal of Physiology. 279:2000;G1-G6.
32. 1 receptor knock-out mice. Science. 283:1999;401-404.
33. Lichtman A.H., Cook S.A., Martin B.R. Investigation of brain sites mediating cannabinoid-induced antinociception in rats: Evidence supporting periaqueductal gray involvement. Journal of Pharmacology & Experimental Therapeutics. 276:1996;585-593.
34. Mani S.K. Progesterone receptor and dopamine receptors are required in Delta 9-tetrahydrocannabinol modulation of sexual receptivity in female rats. [see comments.]. Proceedings of the National Academy of Sciences of the United States of America. 98:2001;1249-1254.
35. Manning B.H., Mayer D.J. The central nucleus of the amygdala contributes to the production of morphine antinociception in the formalin test. Pain. 63:1995;141-152.
36. Manning B.H., Mayer D.J. The central nucleus of the amygdala contributes to the production of morphine antinociception in the rat tail-flick test. Journal of Neuroscience. 15:1995;8199-8213.
37. Mansour A. Anatomy of CNS opioid receptors. Trends in Neurosciences. 11:1988;308-314.
38. Manzanares J., Corchero J., Romero J., Fernández-Ruiz J.J., Ramos J.A., Fuentes J.A. Pharmacological and biochemical interactions between opioids and cannabinoids. Trends in Pharmacological Sciences. 20:1999;287-294.
39. Mas-Nieto M., Pommier B., Tzavara E.T., Caneparo A., Da Nascimento S., Le Fur G., Rogues B.P., Noble F. Reduction of opioid dependence by the CB1 antagonist SR141716A in mice: Evaluation of the interest in pharmacotherapy of opioid addiction. British Journal of Pharmacology. 132:2001;1809-1816.
40. McGregor I.S., Arnold J.C., Weber M.F., Topple A.N., Hunt G.E. A comparison of Δ9-THC and anandamide induced c-fos expression in the rat forebrain. Brain Research. 802:1998;19-26.
41. McGregor I.S., Dastur F.N., McLellan R.A., Brown R.E. Cannabinoid modulation of rat pup ultrasonic vocalizations. European Journal of Pharmacology. 313:1996;43-49.
42. Melis M., Gessa G.L., Diana M. Different mechanisms for dopaminergic excitation induced by opiates and cannabinoids in the rat midbrain. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 24:2000;993-1006.
43. 9-tetrahydrocannabinol-induced expression of Fos protein in the rat brain. Brain Research. 710:1996;234-240.
44. Navarro M., Carrera M.R., Fratta W., Valverde O., Cossu G., Fattore L., Chowen J.A., Gomez R., del Arco I., Villanua M.A., Maldonado R., Koob G.F., de Fonseca F.R. Functional interaction between opioid and cannabinoid receptors in drug self-administration. Journal of Neuroscience. 21:2001;5344-5350.
45. Onaivi E.S., Green M.R., Martin B.R. Pharmacological characerization of cannabinoids in the elevated plus maze. Journal of Pharmacology and Experimental Therapeutics. 253:1990;1002-1009.
46. Park T.H. Neuroanatomical patterns of fos-like immunoreactivity induced by a palatable meal and meal-paired environment in saline- and naltrexone-treated rats. Brain Research. 805:1998;169-180.
47. Patel N.A., Moldow R.L., Patel J.A., Wu G.D., Chang S.L. Arachidonylethanolamide (AEA) activation of FOS proto-oncogene protein immunoreactivity in the rat brain. Brain Research. 797:1998;225-233.
48. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 1997;Academic Press, San Diego, CA.
49. Pomonis J.D., Jewett D.C., Kotz C.M., Briggs J.E., Billington C.J., Levine A.S. Sucrose consumption increases naloxone-induced c-Fos immunoreactivity in limbic forebrain. American Journal of Physiology - Regulatory Integrative & Comparative Physiology. 278:2000;R712-R719.
50. Pomonis J.D., Levine A.S., Billington C.J. Interaction of the hypothalamic paraventricular nucleus and central nucleus of the amygdala in naloxone blockade of neuropeptide gamma-induced feeding revealed by c-fos expression. Journal of Neuroscience. 17:1997;5175-5182.
51. Pontieri F.E., Monnazzi P., Scontrini A., Buttarelli F.R., Patacchioli F.R. Behavioral sensitization to heroin by cannabinoid pretreatment in the rat. European Journal of Pharmacology. 421:2001;R1-R3.
52. Pontieri F.E., Monnazzi P., Scontrini A., Buttarelli F.R., Patacchioli F.R. Behavioral sensitization to WIN55212.2 in rats pretreated with heroin. Brain Research. 898:2001;178-180.
53. Reche I., Fuentes J.A., Ruiz-Gayo M. Potentiation of Δ9-tetrahydrocannabinol-induced analgesia by morphine in mice: Involvement of μ- and k-opioid receptors. European Journal of Pharmacology. 318:1996;11-16.
54. Reilly D., Didcott P., Swift W., Hall W. Long-term cannabis use - characteristics of users in an Australian rural area. Addiction. 93:1998;837-846.
55. Risold P.Y., Thompson R.H., Swanson L.W. The structural organization of connections between hypothalamus and cerebral cortex. Brain Research Reviews. 24:1997;197-254.
56. Rodgers R.J. Effect of naloxone on the behaviour of rats exposed to a novel environment. Psychopharmacologia. 65:1979;103-105.
57. Rodriguez J.J., Mackie K., Pickel V.M. Ultrastructural localization of the CB1 cannabinoid receptor in μ-opioid receptor patches of the rat audate putamen nucleus. Journal of Neuroscience. 21:2001;823-833.
58. Rowland N.E., Mukherjee M., Robertson K. Effects of the cannabinoid receptor antagonist SR 141716, alone and in combination with dexfenfluramine or naloxone, on food intake in rats. Psychopharmacology. 159:2001;111-116.
59. Shu S.Y., Ju G., Fan L.Z. The glucose oxidase-DAB-nickel method in peroxidase histochemistry of the nervous system. Neuroscience Letters. 85:1988;169-171.
60. Smith F.L., Cichewicz D., Martin Z.L., Welch S.P. The enhancement of morphine antinociception in mice by Δ9-tetrahydrocannabinol. Pharmacology, Biochemistry & Behavior. 60:1998;559-566.
61. Szabo B., Dorner L., Pfreundtner C., Norenberg W., Starke K. Inhibition of gabaergic inhibitory postsynaptic currents by cannabinoids in rat corpus striatum. Neuroscience. 85:1998;395-403.
62. 1 opioid receptor mechanism. Science. 276:1997;2048-2050.
63. Wang H., Moriwaki A., Wang J.B., Uhl G.R., Pickel V.M. Ultrastructural immunocytochemical localization of mu-opioid receptors in dendritic targets of dopaminergic terminals in the rat caudate-putamen nucleus. Neuroscience. 81:1997;757-771.
64. Welch S.P. Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice. Journal of Pharmacology & Experimental Therapeutics. 262:1992;10-18.
65. Welch S.P., Eads M. Synergistic interactions of endogenous opioids and cannabinoid systems. Brain Research. 848:1999;183-190.
66. Williams C.M., Kirkham T.C. Reversal of Delta(9)-THC hyperphagia by SR141716 and naloxone but not dexfenfluramine. Pharmacology, Biochemistry & Behavior. 71:2002;333-340.